EC Number |
General Information |
Reference |
---|
2.3.3.14 | malfunction |
an hcsA deletion mutant is lysine auxotrophic and unable to germinate on unhydrolyzed proteins given as a sole nutrient source. The mutant grows on blood and serum, indicating the existence of high-affinity lysine uptake systems. The virulence of the mutant is strongly attenuated in murine models of bronchopulmonary aspergillosis. The mutant retains full virulence when injected intravenously |
-, 719384 |
2.3.3.14 | malfunction |
deletion of the homocitrate synthase gene suppresses htz1D DNA damage sensitivity |
719553 |
2.3.3.14 | malfunction |
nifV-disruption (DELTAnifV) mutant of Bradyrhizobium DOA9 shows significantly less nitrogenase activity in a free-living state than the respective wild-type strain |
757613 |
2.3.3.14 | malfunction |
nifV-disruption (DELTAnifV) mutant of Bradyrhizobium SUTN9-2 shows significantly less nitrogenase activity in a free-living state than the respective wild-type strain |
757613 |
2.3.3.14 | metabolism |
nifV of DOA9 is involved in acetylene reduction activity under free-living conditions, but not in symbiosis with Aeschynomene americana |
757613 |
2.3.3.14 | metabolism |
reaction is the first step in the lysine biosynthetic pathway through alpha-aminoadipate |
704600, 704692 |
2.3.3.14 | metabolism |
the enzyme catalyzes the first and committed step of the alpha-aminoadipate pathway |
-, 756728 |
2.3.3.14 | metabolism |
the enzyme catalyzes the formation of homocitrate, which is essential for arranging the FeMo-cofactor in the catalytic center of nitrogenase. Bradyrhizobium ORS285, a symbiont of Aeschynomene cross-inoculation groups 2 and 3, requires nifV for symbiosis with Aeschynomene species that belong to CI group 3, and some species belonging to CI group 2 |
757613 |
2.3.3.14 | metabolism |
the enzyme is required for free-living and symbiotic dinitrogen fixation with Nod factorF-independent Aeschynomene species |
758410 |
2.3.3.14 | metabolism |
the first committed step in the lysine biosynthetic pathway is catalyzed by the Lys20 and Lys21 homocitrate synthase isoforms. The Lys20 isoform exerts high control over L-lysine flux, while isoform Lys21 exerts low control over the alpha-aminoadipate-pathway flux |
-, 720500 |